Monte Rosa Therapeutics (GLUE) Income from Continuing Operations (2023 - 2025)
Historic Income from Continuing Operations for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$27.1 million.
- Monte Rosa Therapeutics' Income from Continuing Operations fell 1350.43% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 11751.67%. This contributed to the annual value of -$72.7 million for FY2024, which is 4626.6% up from last year.
- According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Income from Continuing Operations is -$27.1 million, which was down 1350.43% from -$12.3 million recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Income from Continuing Operations ranged from a high of $46.9 million in Q1 2025 and a low of -$35.2 million during Q2 2023
- For the 3-year period, Monte Rosa Therapeutics' Income from Continuing Operations averaged around -$18.2 million, with its median value being -$30.3 million (2024).
- Examining YoY changes over the last 5 years, Monte Rosa Therapeutics' Income from Continuing Operations showed a top increase of 24658.43% in 2025 and a maximum decrease of 1350.43% in 2025.
- Monte Rosa Therapeutics' Income from Continuing Operations (Quarter) stood at -$33.3 million in 2023, then soared by 140.32% to $13.4 million in 2024, then crashed by 301.99% to -$27.1 million in 2025.
- Its Income from Continuing Operations was -$27.1 million in Q3 2025, compared to -$12.3 million in Q2 2025 and $46.9 million in Q1 2025.